Physician profile
David J Amrol
NPI 1255308219
$171,679.82
in general payments reported to CMS, 2019-2025
26 companies · $30K in 2025
The $30K reported for 2025 was more than what 95% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $1,681 · 2021: $17K · 2022: $33K · 2023: $49K · 2024: $41K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Travel and Lodging: $10K · Food and Beverage: $9,286 · Consulting Fee: $2,180 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,451.67 |
| Travel and Lodging | $10,120.75 |
| Food and Beverage | $9,286.18 |
| Consulting Fee | $2,180.00 |
| Education | $211.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $96,725.32 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Incyte Corporation | $32,236.76 | 2022-2025 | Opzelura |
| Ionis Pharmaceuticals, INC. | $21,509.89 | 2025 | Dawnzera |
| Amgen INC. | $9,539.42 | 2021-2025 | Tezspire |
| Genzyme Corporation | $2,905.50 | 2021-2025 | |
| Csl Behring | $2,382.66 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Biocryst US Sales Co., LLC | $1,546.01 | 2021-2025 | Orladeyo |
| Biocryst Pharmaceuticals, INC. | $1,375.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $595.33 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $445.68 | 2021-2025 | Dupixent |
| Pharming Healthcare, INC. | $418.21 | 2021-2025 | Ruconest |
| Pfizer INC. | $332.80 | 2020-2025 | |
| Glaxosmithkline, LLC. | $281.76 | 2021-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $268.28 | 2023-2025 | Cuvitru |
| Optinose US, INC. | $208.48 | 2021-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $157.61 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $151.99 | 2023-2025 | |
| Abbvie INC. | $137.32 | 2022-2024 | Rinvoq |
| Ethicon US, LLC | $95.39 | 2019 | |
| Grifols Shared Services North America, INC. | $84.75 | 2023 | Xembify |
| Cycle Pharmaceuticals INC | $73.45 | 2025 | Sajazir |
| Grifols USA, LLC | $68.50 | 2024-2025 | Xembify |
| Hikma Pharmaceuticals USA | $57.15 | 2022-2023 | Ryaltris |
| Lilly USA, LLC | $51.03 | 2024-2025 | Ebglyss |
| Azurity Pharmaceuticals, INC. | $16.68 | 2025 | Alvesco |
| Alk-Abello, INC | $14.85 | 2023 | Ragwitek, Odactra, Grastek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Amrol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.